Coca-Cola cases recalled due to plastic contamination
Coca-Cola has issued a recall on select cases of its soda due to foreign object contamination.
Reyes Coca-Cola Bottling, LLC issued the voluntary recall earlier this month, according to a report shared by the Food and Drug Administration (FDA).
A total of 864 cases — each of which has 12 Coca-Cola cans — have been recalled because they were contaminated with plastic. This means that more than 10,000 cans of soda were affected by the recall.
According to the FDA, each of the affected cans has a UPC of 0 49000-00634 6. The targeted packs of 12 cans have a UPC of 0 49000-02890 4.
The recalled cases of Coca-Cola were distributed to retailers in Illinois and Wisconsin.
The action was classified as a 'Class II' recall on Monday, which is a 'situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote,' according to the FDA.
The Independent has contacted Reyes Coca-Cola Bottling, LLC for comment.
The news comes as food and drink recalls continue to be on the rise.
Last week, Aldi issued a voluntary recall on 400 cases of Happy Farm's Colby Jack Deli Sliced Cheese, which included 12 plastic pouches of blended Colby and Monterey cheese slices each.
According to the FDA, the Aldi product may contain stainless steel fragments, and exposure to such contaminants could cause temporary health risks. It's unclear how the potential metal products got into the cheese.
Days earlier, Dessert Holdings, LLC announced that it was recalling a Target brand cheesecake. The product is Favorite Day's New York Style Cheesecake, sold in a six-ounce container with two slices of cake.
The cheesecake was recalled due to mislabeled packaging, resulting in undeclared pecans in the products. Customers who 'have an allergy or severe sensitivity to pecans run the risk of serious or life-threatening allergic reactions' if they consume this cheesecake, states a press release concerning the recall.
Recalled cheesecakes were sent to Target Distribution Centers in California, Florida, Iowa, Ohio, and Texas. The product was sold at Target stores in these states.
Also this month, Nestlé U.S. issued a voluntary recall on a limited supply of its Stouffer's and Lean Cuisine meals due to the potential presence of 'wood-like material.' The food conglomerate said the recalled products had been distributed 'at major retailers' between September 2024 and March 2025.
Nestlé said the company launched an investigation after consumers contacted them to report multiple issues — one involving a potential choking incident.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Engadget
3 hours ago
- Engadget
How to buy the Nintendo Switch 2: Latest stock availability for consoles and games
The Nintendo Switch 2 is finally a thing you can buy in the US. The $450 console officially went up for sale at midnight ET on June 5, with several retailers offering the device both online and in-store. Predictably, online stock dried up fairly quickly and remains extremely limited as of our last sweep on Friday afternoon. This goes for Target too, which began its online sales around 3:30AM ET on June 6. Broadly speaking, people seem to have had more luck by going to a physical retail store in person. We can't guarantee you'll be able to snag one that way, but a few Engadget staffers managed to grab a Switch 2 on Thursday at their local Target or GameStop, even without a pre-order in place. So before you call it quits, check if a nearby Target, GameStop, Walmart or Best Buy — the four official retailers Nintendo lists on its store page — still has consoles in stock. If you're still on the hunt for Nintendo's newest device, we're rounding up all of the information we can find on how to buy the Nintendo Switch 2 and where you can pick one up. Walmart opened up online purchases at midnight ET on June 5, but both the console alone and Nintendo's Mario Kart World bundle are out of stock as our latest update. Naturally, the world's largest retailer is also selling the console at its brick-and-mortar locations. The company has noted that quantities are limited and inventory will vary by location, but it's worth seeing if any store near you still has devices available. Target began selling the Switch 2 in stores on June 5. The retailer warned that supply will be limited and the console may now be sold out, though it's still worth looking into the locations closest to you. Anecdotally, Engadget's Billy Steele was able to pick up a Switch 2 at a Target just outside of Greensboro, NC as late as 4:15pm ET on Thursday. The company restocked its online inventory around 3:30AM ET on Friday, June 6. Those listings were live for at least a couple of hours, which is longer than we would've expected, but they've since gone out of stock. GameStop held launch events on Wednesday and has advertised in-store availability, though again this will vary by location. Engadget's Cherlynn Low was able to buy the console without a pre-order at a GameStop store in the New York City area on Thursday morning. That particular location had a little under 80 units available, but its manager told Low that inventory would differ at other stores based on population. The device is currently unavailable on GameStop's website. A $625 bundle that includes Mario Kart World , a microSD Express card and a few other accessories has been in and out of stock a bit more frequently than the standard SKUs, though it's sold out now (and kind of scummy anyway). We briefly saw it return on Thursday afternoon, so it may be one to bookmark if you can stomach the extra cost. The listings for the base console and Mario Kart bundle, meanwhile, now point to a "Find a Store" page. Best Buy held in-store launch events and said it'd have limited stock at its retail locations starting June 5. It is not selling the console online during launch week, however. You may have some luck at certain membership-based retailers. A Mario Kart World bundle at Costco that includes a 12-month Switch Online subscription has gone in and out of stock since Thursday morning, while Sam's Club has had a bundle without the Switch Online sub as well. You'll need a membership to check on either of those, though. We also saw the console at BJ's early on Thursday, but that retailer is also out of stock as of Friday afternoon. Verizon briefly had the Switch 2 available on Thursday morning, but that's dried up, and only those with Verizon service were able to order. Amazon doesn't have any form of Switch 2 listing on its website, nor does it list first-party Switch 2 games like Mario Kart World and Donkey Kong Bananza . The company didn't take any pre-orders for the Switch 2 either, so it's unclear if and when it will sell the device. Newegg has listed the Switch 2 on its site for several weeks, but it hasn't started sales yet. With all of these stores, we've seen the Mario Kart World bundle available in greater quantities online than the base console, which costs $50 less. But considering Mario Kart is the Switch 2's biggest launch game and retails for $80 on its own, that may not be the worst thing. Nintendo, meanwhile, is only offering the Switch 2 via an invite system. This requires you to have been a Switch Online member for at least 12 months and logged at least 50 hours of Switch 1 playtime as of April 2. It can't hurt to sign up if you meet the criteria, but don't expect it to bear fruit immediately — many people who registered in April still haven't received an invite, and shipments haven't arrived yet for some who did order. You can find a list of every Switch 2 retail listing we could find below. Just be aware that this is meant to be a reference, not a rundown of everywhere the device is available right this second. Where to buy Switch 2 + Mario Kart World bundle: Where to buy Switch 2: Unsurprisingly, Nintendo is selling a number of Switch 2 accessories alongside the console, from controllers to cases to cameras that utilize the system's new GameChat feature. Most of these became available on June 5 as well. The same goes for games like Mario Kart World and the Switch 2 version of The Legend of Zelda: Tears of the Kingdom . Another big Switch 2 release, Donkey Kong Bananza , won't be available until mid-July, though you can still pre-order it today. As of Friday afternoon, just about all Switch 2 games remain widely available. Stock for the accessories is spottier, but most devices are still available at one or two retailers at minimum. Nintendo's official Switch 2 carrying cases seem to be the hardest to find right now. Mario Kart World ($80) Nintendo Walmart GameStop Best Buy Target Donkey Kong Bananza ($70) Nintendo Walmart GameStop Best Buy Target Costco (membership required) Additional Switch 2 games Nintendo Amazon Walmart GameStop Best Buy Target Samsung microSD Express Card (256GB) for Nintendo Switch 2 ($60) Nintendo Walmart GameStop Best Buy Target Amazon Joy-Con 2 bundle ($95) Nintendo Walmart GameStop Best Buy Target Switch 2 Pro Controller ($85) Switch 2 Camera ($55) Nintendo Walmart GameStop Best Buy Target Hori Nintendo Switch 2 Piranha Plant Camera ($60) Joy-Con 2 Charging Grip ($40) Nintendo Walmart GameStop Best Buy Target Joy-Con 2 Wheels (set of 2) ($25) Nintendo Walmart GameStop Best Buy Target Switch 2 All-in-One Carrying Case ($85) Nintendo Walmart GameStop Best Buy Target Switch 2 Carrying Case and Screen Protector ($40) Nintendo (invite required) Walmart GameStop Best Buy Target Nintendo Switch 2 Dock Set ($120)
Yahoo
4 hours ago
- Yahoo
HistoSonics completes pivotal histotripsy system trial enrolment
As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company's prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm. Patients will be treated with the Edison system and followed for five years post-procedure, with data at the 90-day evaluation point to be submitted in support of regulatory approval with the US Food and Drug Administration (FDA). The Edison system uses a technology called histotripsy, involving the delivery of non-thermal, non-invasive focused ultrasound waves to target and eliminate cancerous liver tissue. The system received de novo clearance from the US Food and Drug Administration (FDA) in 2023 and last month secured its first major insurance coverage from a new healthcare policy from Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network. HistoSonics' vision is for its Edison system to become a 'foundational, non-invasive' solution across a range of clinical applications, the company's CEO, Mike Blue stated. 'Completing enrolment in our pivotal kidney tumour trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumour types and indications,' said Blue. In May, Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet Clinical Need Authorisation (UCNA) under the UK's Innovative Devices Access Pathway (IDAP), launched by the UK Government in 2023 to help fast-track 'transformative medical technologies' into the healthcare system. As first reported by the Financial Times last month, HistoSonics is seeking a valuation of more than $2.5bn for a takeover of the company, with Medtronic, GE HealthCare and Johnson & Johnson (J&J), a longtime backer of HistoSonics, among the interested parties evaluating the business. J&J most recently participated in HistoSonics' $102m Series D funding round. "HistoSonics completes pivotal histotripsy system trial enrolment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
4 hours ago
- Yahoo
Phathom Pharmaceuticals shares soar on FDA exclusivity grant
-- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company's petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock's movement. The FDA's response to Phathom's citizen petition, which was received on December 11, 2024, allows the company to benefit from the extended exclusivity initially granted to Voquezna Triple Pak and Voquezna Dual Pak. These packages, which contain the new chemical entity (NCE) vonoprazan, were designated as qualified infectious disease products (QIDPs) and received an additional 5 years of exclusivity, totaling 10 years under the GAIN provisions. The FDA's decision is in line with its umbrella policy, which aims to encourage the development and improvement of drugs containing the NCE without compromising the innovator's exclusivity period. This FDA ruling is pivotal for Phathom as it ensures that Voquezna will benefit from the remainder of the NCE exclusivity recognized for the Voquezna Paks. The Orange Book will be updated to accurately reflect this extended period of exclusivity, which is a substantial win for the company. This exclusivity extension is particularly important as it protects Voquezna from generic competition and allows Phathom to capitalize on the market potential of its product without immediate threats. Related articles Phathom Pharmaceuticals shares soar on FDA exclusivity grant Neo Performance Materials stock surges on buyback plan BofA sees termination of Owens–Rotech deal as surprising but potentially positive Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data